APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Depression Drugs

Depression is a mental health issue. It’s a condition that starts most often in early adulthood. It’s also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used for Depression.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Depression is a mental health issue. It’s a condition that starts most often in early adulthood. It’s also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used for Depression.

Selected research

Market Analysis & Forecast

Global Depression Drugs Market Analysis and Forecast 2026-2032

Report ID 173893980222 December 2025197 pages

Choose your research edition.

Industry ResearchDepression Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Depression Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Depression Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Depression Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Depression Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Depression is a mental health issue. It’s a condition that starts most often in early adulthood. It’s also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used for Depression.

Global Depression Drugs key players include Intellipharmaceutics, Pfizer, Eli Lilly, Astrazeneca, Lundbeck, etc. Global top five manufacturers hold a share over 35%.

North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share about 50%.

Read the full market overview

In terms of product, SSRIs is the largest segment, with a share over 45%. And in terms of application, the largest application is Hospitals, followed by Clinics, etc.

Report Includes

This report presents an overview of global market for Depression Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Depression Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Depression Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Depression Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Depression Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Depression Drugs revenue, projected growth trends, production technology, application and end-user industry.

Depression Drugs Segment by Company

Intellipharmaceutics

Pfizer

Eli Lilly

Astrazeneca

Lundbeck

Allergan

GSK

Otsuka Pharmaceutical

Takeda

NHU Group

Shionogi

APOTEX

Kanghong Pharma

HUAHAI

Depression Drugs Segment by Type

SSRIs

SNRIs

Others

Depression Drugs Segment by Application

Hospitals

Clinics

Others

Depression Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Depression Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Depression Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Depression Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Depression Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Depression Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Depression Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Depression Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. SSRIs Major Player Table 3. SNRIs Major Player Table 4. Others Major Player Table 5. Global Depression Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Player Table 7. Clinics Major Player Table 8. Others Major Player Table 9. Depression Drugs Industry Trends Table 10. Depression Drugs Industry Drivers Table 11. Depression Drugs Industry Opportunities and Challenges Table 12. Depression Drugs Industry Restraints Table 13. Global Depression Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Depression Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Depression Drugs Market Share by Region (2021-2026) Table 16. Global Depression Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Depression Drugs Market Share by Region (2027-2032) Table 18. Global Depression Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Depression Drugs Revenue Market Share by Players (2021-2026) Table 20. Global Depression Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Depression Drugs Key Players Headquarters & Area Served Table 22. Global Depression Drugs Players, Product Type & Application Table 23. Global Depression Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Depression Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Depression Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Depression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Depression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Depression Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Depression Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Depression Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Depression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Depression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Depression Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Depression Drugs Revenue Market Share by Application (2027-2032) Table 36. Intellipharmaceutics Company Information Table 37. Intellipharmaceutics Business Overview Table 38. Intellipharmaceutics Depression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Intellipharmaceutics Depression Drugs Product Portfolio Table 40. Intellipharmaceutics Recent Development Table 41. Pfizer Company Information Table 42. Pfizer Business Overview Table 43. Pfizer Depression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Pfizer Depression Drugs Product Portfolio Table 45. Pfizer Recent Development Table 46. Eli Lilly Company Information Table 47. Eli Lilly Business Overview Table 48. Eli Lilly Depression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Eli Lilly Depression Drugs Product Portfolio Table 50. Eli Lilly Recent Development Table 51. Astrazeneca Company Information Table 52. Astrazeneca Business Overview Table 53. Astrazeneca Depression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Astrazeneca Depression Drugs Product Portfolio Table 55. Astrazeneca Recent Development Table 56. Lundbeck Company Information Table 57. Lundbeck Business Overview Table 58. Lundbeck Depression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Lundbeck Depression Drugs Product Portfolio Table 60. Lundbeck Recent Development Table 61. Allergan Company Information Table 62. Allergan Business Overview Table 63. Allergan Depression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Allergan Depression Drugs Product Portfolio Table 65. Allergan Recent Development Table 66. GSK Company Information Table 67. GSK Business Overview Table 68. GSK Depression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. GSK Depression Drugs Product Portfolio Table 70. GSK Recent Development Table 71. Otsuka Pharmaceutical Company Information Table 72. Otsuka Pharmaceutical Business Overview Table 73. Otsuka Pharmaceutical Depression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Otsuka Pharmaceutical Depression Drugs Product Portfolio Table 75. Otsuka Pharmaceutical Recent Development Table 76. Takeda Company Information Table 77. Takeda Business Overview Table 78. Takeda Depression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Takeda Depression Drugs Product Portfolio Table 80. Takeda Recent Development Table 81. NHU Group Company Information Table 82. NHU Group Business Overview Table 83. NHU Group Depression Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. NHU Group Depression Drugs Product Portfolio Table 85. NHU Group Recent Development Table 86. Shionogi Company Information Table 87. Shionogi Business Overview Table 88. Shionogi Depression Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 89. Shionogi Depression Drugs Product Portfolio Table 90. Shionogi Recent Development Table 91. APOTEX Company Information Table 92. APOTEX Business Overview Table 93. APOTEX Depression Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 94. APOTEX Depression Drugs Product Portfolio Table 95. APOTEX Recent Development Table 96. Kanghong Pharma Company Information Table 97. Kanghong Pharma Business Overview Table 98. Kanghong Pharma Depression Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 99. Kanghong Pharma Depression Drugs Product Portfolio Table 100. Kanghong Pharma Recent Development Table 101. HUAHAI Company Information Table 102. HUAHAI Business Overview Table 103. HUAHAI Depression Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 104. HUAHAI Depression Drugs Product Portfolio Table 105. HUAHAI Recent Development Table 106. North America Depression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 107. North America Depression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 108. North America Depression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 109. North America Depression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 110. North America Depression Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. North America Depression Drugs Revenue by Country (2021-2026) & (US$ Million) Table 112. North America Depression Drugs Revenue by Country (US$ Million) & (2027-2032) Table 113. Europe Depression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 114. Europe Depression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 115. Europe Depression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 116. Europe Depression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 117. Europe Depression Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Europe Depression Drugs Revenue by Country (2021-2026) & (US$ Million) Table 119. Europe Depression Drugs Revenue by Country (US$ Million) & (2027-2032) Table 120. China Depression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 121. China Depression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 122. China Depression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 123. China Depression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia Depression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 125. Asia Depression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 126. Asia Depression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 127. Asia Depression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Depression Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Asia Depression Drugs Revenue by Region (US$ Million) & (2021-2026) Table 130. Asia Depression Drugs Revenue by Region (US$ Million) & (2027-2032) Table 131. SAMEA Depression Drugs Revenue by Type (2021-2026) & (US$ Million) Table 132. SAMEA Depression Drugs Revenue by Type (2027-2032) & (US$ Million) Table 133. SAMEA Depression Drugs Revenue by Application (2021-2026) & (US$ Million) Table 134. SAMEA Depression Drugs Revenue by Application (2027-2032) & (US$ Million) Table 135. SAMEA Depression Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. SAMEA Depression Drugs Revenue by Country (2021-2026) & (US$ Million) Table 137. SAMEA Depression Drugs Revenue by Country (US$ Million) & (2027-2032) Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Depression Drugs Image Figure 2. Global Depression Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Depression Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. SSRIs Image Figure 5. SNRIs Image Figure 6. Others Image Figure 7. Global Depression Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Depression Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Others Image Figure 12. Global Depression Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global Depression Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Depression Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Depression Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Depression Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Depression Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Depression Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global Depression Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Depression Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Depression Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Depression Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Depression Drugs Revenue Share by Type (2021-2032) Figure 25. North America Depression Drugs Revenue Share by Application (2021-2032) Figure 26. North America Depression Drugs Revenue Share by Country (2021-2032) Figure 27. United States Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Depression Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Depression Drugs Revenue Share by Type (2021-2032) Figure 32. Europe Depression Drugs Revenue Share by Application (2021-2032) Figure 33. Europe Depression Drugs Revenue Share by Country (2021-2032) Figure 34. Germany Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Depression Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Depression Drugs Revenue Share by Type (2021-2032) Figure 44. China Depression Drugs Revenue Share by Application (2021-2032) Figure 45. Asia Depression Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Depression Drugs Revenue Share by Type (2021-2032) Figure 47. Asia Depression Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Depression Drugs Revenue Share by Region (2021-2032) Figure 49. Japan Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Depression Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Depression Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA Depression Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA Depression Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Depression Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • SSRIs
  • SNRIs
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Intellipharmaceutics
  • Pfizer
  • Eli Lilly
  • Astrazeneca
  • Lundbeck
  • Allergan
  • GSK
  • Otsuka Pharmaceutical
  • Takeda
  • NHU Group
  • Shionogi
  • APOTEX
  • Kanghong Pharma
  • HUAHAI

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Depression Drugs Market by Type
  3. 1.2.1 Global Depression Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 SSRIs
  5. 1.2.3 SNRIs
  6. 1.2.4 Others
  7. 1.3 Depression Drugs Market by Application
  8. 1.3.1 Global Depression Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Depression Drugs Market Dynamics
  1. 2.1 Depression Drugs Industry Trends
  2. 2.2 Depression Drugs Industry Drivers
  3. 2.3 Depression Drugs Industry Opportunities and Challenges
  4. 2.4 Depression Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Depression Drugs Market Perspective (2021-2032)
  2. 3.2 Global Depression Drugs Growth Trends by Region
  3. 3.2.1 Global Depression Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Depression Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Depression Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Depression Drugs Revenue by Players
  2. 4.1.1 Global Depression Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Depression Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Depression Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Depression Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Depression Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Depression Drugs Players, Product Type & Application
  8. 4.5 Global Depression Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Depression Drugs Market CR5 and HHI
  11. 4.6.3 2025 Depression Drugs Tier 1, Tier 2, and Tier 3
5 Depression Drugs Market Size by Type
  1. 5.1 Global Depression Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Depression Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Depression Drugs Revenue Market Share by Type (2021-2032)
6 Depression Drugs Market Size by Application
  1. 6.1 Global Depression Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Depression Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Depression Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Intellipharmaceutics
  2. 7.1.1 Intellipharmaceutics Company Information
  3. 7.1.2 Intellipharmaceutics Business Overview
  4. 7.1.3 Intellipharmaceutics Depression Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Intellipharmaceutics Depression Drugs Product Portfolio
  6. 7.1.5 Intellipharmaceutics Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Depression Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Depression Drugs Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 Eli Lilly
  14. 7.3.1 Eli Lilly Company Information
  15. 7.3.2 Eli Lilly Business Overview
  16. 7.3.3 Eli Lilly Depression Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lilly Depression Drugs Product Portfolio
  18. 7.3.5 Eli Lilly Recent Developments
  19. 7.4 Astrazeneca
  20. 7.4.1 Astrazeneca Company Information
  21. 7.4.2 Astrazeneca Business Overview
  22. 7.4.3 Astrazeneca Depression Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Astrazeneca Depression Drugs Product Portfolio
  24. 7.4.5 Astrazeneca Recent Developments
  25. 7.5 Lundbeck
  26. 7.5.1 Lundbeck Company Information
  27. 7.5.2 Lundbeck Business Overview
  28. 7.5.3 Lundbeck Depression Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Lundbeck Depression Drugs Product Portfolio
  30. 7.5.5 Lundbeck Recent Developments
  31. 7.6 Allergan
  32. 7.6.1 Allergan Company Information
  33. 7.6.2 Allergan Business Overview
  34. 7.6.3 Allergan Depression Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Allergan Depression Drugs Product Portfolio
  36. 7.6.5 Allergan Recent Developments
  37. 7.7 GSK
  38. 7.7.1 GSK Company Information
  39. 7.7.2 GSK Business Overview
  40. 7.7.3 GSK Depression Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GSK Depression Drugs Product Portfolio
  42. 7.7.5 GSK Recent Developments
  43. 7.8 Otsuka Pharmaceutical
  44. 7.8.1 Otsuka Pharmaceutical Company Information
  45. 7.8.2 Otsuka Pharmaceutical Business Overview
  46. 7.8.3 Otsuka Pharmaceutical Depression Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Otsuka Pharmaceutical Depression Drugs Product Portfolio
  48. 7.8.5 Otsuka Pharmaceutical Recent Developments
  49. 7.9 Takeda
  50. 7.9.1 Takeda Company Information
  51. 7.9.2 Takeda Business Overview
  52. 7.9.3 Takeda Depression Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Takeda Depression Drugs Product Portfolio
  54. 7.9.5 Takeda Recent Developments
  55. 7.10 NHU Group
  56. 7.10.1 NHU Group Company Information
  57. 7.10.2 NHU Group Business Overview
  58. 7.10.3 NHU Group Depression Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 NHU Group Depression Drugs Product Portfolio
  60. 7.10.5 NHU Group Recent Developments
  61. 7.11 Shionogi
  62. 7.11.1 Shionogi Company Information
  63. 7.11.2 Shionogi Business Overview
  64. 7.11.3 Shionogi Depression Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Shionogi Depression Drugs Product Portfolio
  66. 7.11.5 Shionogi Recent Developments
  67. 7.12 APOTEX
  68. 7.12.1 APOTEX Company Information
  69. 7.12.2 APOTEX Business Overview
  70. 7.12.3 APOTEX Depression Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 APOTEX Depression Drugs Product Portfolio
  72. 7.12.5 APOTEX Recent Developments
  73. 7.13 Kanghong Pharma
  74. 7.13.1 Kanghong Pharma Company Information
  75. 7.13.2 Kanghong Pharma Business Overview
  76. 7.13.3 Kanghong Pharma Depression Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Kanghong Pharma Depression Drugs Product Portfolio
  78. 7.13.5 Kanghong Pharma Recent Developments
  79. 7.14 HUAHAI
  80. 7.14.1 HUAHAI Company Information
  81. 7.14.2 HUAHAI Business Overview
  82. 7.14.3 HUAHAI Depression Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 HUAHAI Depression Drugs Product Portfolio
  84. 7.14.5 HUAHAI Recent Developments
8 North America
  1. 8.1 North America Depression Drugs Revenue (2021-2032)
  2. 8.2 North America Depression Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Depression Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Depression Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Depression Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Depression Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Depression Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Depression Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Depression Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Depression Drugs Revenue by Country
  11. 8.6.1 North America Depression Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Depression Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Depression Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Depression Drugs Revenue (2021-2032)
  2. 9.2 Europe Depression Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Depression Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Depression Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Depression Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Depression Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Depression Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Depression Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Depression Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Depression Drugs Revenue by Country
  11. 9.6.1 Europe Depression Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Depression Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Depression Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Depression Drugs Revenue (2021-2032)
  2. 10.2 China Depression Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Depression Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Depression Drugs Revenue by Type (2027-2032)
  5. 10.3 China Depression Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Depression Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Depression Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Depression Drugs Revenue by Application (2027-2032)
  9. 10.5 China Depression Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Depression Drugs Revenue (2021-2032)
  2. 11.2 Asia Depression Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Depression Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Depression Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Depression Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Depression Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Depression Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Depression Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Depression Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Depression Drugs Revenue by Country
  11. 11.6.1 Asia Depression Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Depression Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Depression Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Depression Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Depression Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Depression Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Depression Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Depression Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Depression Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Depression Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Depression Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Depression Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Depression Drugs Revenue by Country
  11. 12.6.1 SAMEA Depression Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Depression Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Depression Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst